SRAM
UTHR icon

Stone Ridge Asset Management’s United Therapeutics UTHR Stock Holding History

Stone Ridge Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,500
Closed -$666K – 1388
2017
Q4 		$666K Buy
+4,500
New +$572K 0.04% 627

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Stone Ridge Asset Management's UTHR Position: Q1 2018 in Review

Stone Ridge Asset Management sold out of United Therapeutics (UTHR) in Q1 2018, closing a stake of 4,500 shares — an estimated $666K sold.

Stone Ridge Asset Management first reported a position in UTHR in Q4 2017 and held it in 1 quarter. The position peaked at $666K in Q4 2017. 374 funds tracked by Wall St. Rank hold UTHR as of Q1 2018.

  • Stone Ridge Asset Management reported no remaining United Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Stone Ridge Asset Management sold 4,500 United Therapeutics shares in Q1 2018, an estimated $666K.
  • Stone Ridge Asset Management first reported a position in United Therapeutics in Q4 2017 and held it in 1 quarter.
  • Stone Ridge Asset Management's United Therapeutics position peaked at $666K in Q4 2017.
  • 374 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2018.

Based on Stone Ridge Asset Management's 13F filing for Q1 2018, filed 14 May 2018.